Back to search

Peptide record

TPDB92321

[D4K,A18K]OCN-3N [D4K]OCN-3N Antibacterial Anticancer Antifungal Toxicity standard
19 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92321
[D4K,A18K]OCN-3N [D4K]OCN-3N
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0 dbACP
standard
No
A 19-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from Peptipedia, CancerPPD 2.0, and dbACP, with an available 3D structural model.
C-terminal: Amidation
Sequence
GIFKVLKNLAKGVITSLKS-NH2
Physicochemical Analysis
C94H166N24O24
RDCEQHMPWY
K
2016.50
11.00
4
0
9
+4
1.34
0.589
138.42
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
4
Residue Composition
number
1
A
0
R
1
N
0
D
0
C
0
E
0
Q
2
G
0
H
2
I
3
L
4
K
0
M
1
F
0
P
2
S
1
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 1 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 2 L: 3 K: 4 M: 0 F: 1 P: 0 S: 2 T: 1 W: 0 Y: 0 V: 2
Chemical Descriptors
19
C94H166N24O24
2016.50
11.00
+4
1.34
0.589
Amidation
L
Linear
Free
Host Defense
Synthetic Derivative of ocellatin-3N
Evidence Records 6 records
Evidence 1 Activity

Activity

LC50
LC50 = 12 ± 1 µM
Anticancer
12

Target

Lung Cancer
A-549
Lung

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LC50
LC50 = 15 ± 1 µM
Anticancer
15

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 3 Activity

Activity

LC50
LC50 = 20 ± 1 µM
Anticancer
20

Target

Colorectal Cancer
HT-29
Colon

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 4 Activity

Activity

LC50
LC50 = 25 ± 1 µM
Anticancer
25

Target

Lung Cancer
A-549
Lung

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 5 Activity

Activity

LC50
LC50 = 31 ± 1 µM
Anticancer
31

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 6 Activity

Activity

LC50
LC50 = 46 ± 12 µM
Anticancer
46

Target

Colorectal Cancer
HT-29
Colon

Assay & Model

CellTiter-Glo assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022